SINGAPORE--(BUSINESS WIRE)--A-Bio Pharma Pte Ltd. today announced that Dr. Steven S. Lee, Ph.D., has joined the company as its Chief Executive Officer. Steve joins A-Bio from pharmaceutical giant Bristol Myers Squibb Company (BMS), where he held the position of Vice President and General Manager of the Syracuse, New York Manufacturing and Process Development Complex overseeing over 800 employees and a wide range of biological drugs and development candidates including antibody therapeutics.
“I am very pleased that Steve has taken the helm at A-Bio,” said Chu Swee Yeok, CEO of Bio*One Capital. “Steve has many years of biologics manufacturing experience. He will bring his invaluable seasoned perspective to A-Bio and lead the company into the next important phase of expansion and exciting growth.”
Bio*One Capital, the main investor in A-Bio, has been instrumental in developing A-Bio as the pioneering biologics player in Singapore. After acquiring Biopharmaceutical Manufacturing Technology Centre (BMTC), A-Bio has grown into a strong provider of a full range of process development and GMP manufacturing services. Its customers include large global pharmaceutical companies as well as biotechnology companies.
“I am delighted to join A-Bio with its experienced team of engineers, scientists and GMP trained employees,” said Dr. Lee. “As the global development and manufacturing hub for biologics, Singapore is in a unique position today; it is located at the center of the talent pools and markets of Australia, China and India at a time when the biotech industry is expanding worldwide. I envision enormous potential for growth for A-Bio as global biologics businesses move to new markets in Asia. A-Bio in Singapore is well positioned to capitalize on such growing opportunities.”
Prior to joining BMS in 2002, Dr. Lee was Director of Fermentation and Cell Culture Development at Merck’s West Point, Pennsylvania vaccine facility, where he held several positions of increasing responsibility at Merck Research Laboratories and Merck Manufacturing Division since joining in 1990. Dr. Lee received his doctorate in Biochemical Engineering from the Massachusetts Institute of Technology and a Master’s in Chemical engineering from the University of Michigan, Ann Arbor.
A-Bio is one of Asia’s leading biologics contract manufacturers. It provides a full range of GMP manufacturing capabilities for biological protein manufacturing scale-up, cGMP production and regulatory compliance. Within four years of operation, A-Bio has established a strong track record with customers such as GlaxoSmithKline Biologicals, Novo Nordisk, Artisan Pharma and others. For more on A-Bio: www.a-bio.com.
About Bio*One Capital
Bio*One Capital, the major shareholder of A-Bio, is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. Its investments are focused on promising global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies’ growth strategies in Asia. Through its extensive networks with global companies and venture capital corporations, Bio*One Capital proactively facilitates partnering and collaborative opportunities to help its portfolio companies grow into sustainable and successful ventures. For more on Bio*One Capital: www.bio1capital.com.
Lara D’Souza, 65515424
Rae Chew, 65515420
Source: A-Bio Pharma Pte Ltd.